GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

46.55 -0.48 (-1.02%)

Official Closing Price Updated: 4:10 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

45 46 Next >

Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy ↗

December 18, 2024

Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS.

Via Investor's Business Daily

AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back? ↗

December 17, 2024

AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025.

Via Investor's Business Daily

What's Going On Moderna Stock On Monday? ↗

December 16, 2024

Moderna faces index removal, stock plunge, vaccine challenges, and lawsuits, while focusing on R&D in oncology and rare diseases for future growth.

Via Benzinga

Topics Lawsuit

Kennedy's Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children ↗

December 13, 2024

Lawyer files petition against polio vaccine, part of broader anti-vaccine campaign by Robert F. Kennedy Jr. and Aaron Siri, causing concerns for vaccine policies and pharma companies. Trump considering...

Via Benzinga

Topics Government

Bird Flu Spreads To Cats, Possibly Horses As Officials Signal No Plans To Authorize Vaccination ↗

December 13, 2024

Avian flu continues to spread with cases in cats, horses, and humans. Scientists monitor wildlife infections. Vaccine development may face challenges.

Via Benzinga

GSK Stock Crumbles As Vaccine Sales Plummet And Miss Expectations ↗

October 30, 2024

The company said revenue from RSV vaccine tumbled 72%.

Via Investor's Business Daily

United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis ↗

December 13, 2024

An analysis of NICE-approved drugs from 2000–2020 reveals trade-offs in NHS resource allocation, with high costs leading to a net loss of population health gains.

Via Benzinga

Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing ↗

December 12, 2024

Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.

Via Benzinga

GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex ↗

December 10, 2024

GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to Darzalex combo.

Via Benzinga

Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse

December 09, 2024

From GSK plc

Via Business Wire

Oracle, Vertiv And A Health Care Stock On CNBC's 'Final Trades' ↗

December 09, 2024

On CNBC's "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors said Oracle is going to report a strong quarter.

Via Benzinga

Bird Flu Found In Raw Milk Leads To Recall In California ↗

November 26, 2024

Bird flu has been detected in a batch of raw milk sold in California and a voluntary recall of the milk has been issued at the request of the state's department of public health.

Via Benzinga

Topics Product Recall

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce ↗

November 26, 2024

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%.

Via Benzinga

Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines? ↗

November 20, 2024

According to the Los Angeles Times, the total bird flue case count in the U.S. stands at 54; 31 cases are attributed to the dairy industry.

Via Benzinga

GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients ↗

November 19, 2024

GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its primary endpoint.

Via Benzinga

European And US Vaccine Stocks Are Under Pressure - Here's WHy ↗

November 15, 2024

Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts.

Via Benzinga

GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why ↗

November 14, 2024

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

Via Benzinga

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease ↗

November 13, 2024

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.

Via Benzinga

Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs ↗

November 12, 2024

23andMe restructures, cutting 40% of its workforce and ending its therapeutic programs to save $35 million annually while exploring strategic alternatives.

Via Benzinga

Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction' ↗

November 07, 2024

Donald Trump has said he will give Robert F. Kennedy Jr. a senior role in his incoming administration to advance his "Make America Healthy Again" agenda.

Via Benzinga

Topics Government

Moderna Posts A Surprise Profit As Sales Wallop Views. But Will RSV Be Its Undoing? ↗

November 07, 2024

The company reported just $10 million in sales of its RSV vaccine, mResvia, widely missing expectations.

Via Investor's Business Daily

Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗

November 01, 2024

The major indexes declined, but haven't fallen apart.

Via Investor's Business Daily

GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024 ↗

October 30, 2024

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines and HIV drugs show growth.

Via Benzinga

Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population ↗

October 24, 2024

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for millions at risk of serious disease.

Via Benzinga

New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease

October 24, 2024

From GSK plc

Via Business Wire

FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years ↗

October 23, 2024

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals to safeguard infants from birth.

Via Benzinga

Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. ↗

October 21, 2024

Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader.

Via Investor's Business Daily

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

October 21, 2024

Via Benzinga

Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology ↗

October 17, 2024

Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines.

Via Benzinga

Topics Lawsuit

GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract Infections, Probably First In New Class In Over 20 Years ↗

October 16, 2024

GSK's gepotidacin, an oral antibiotic for uUTIs, could be the first in over 20 years. The FDA granted Priority Review with a March 2025 decision expected. Trials showed better efficacy than...

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.